| abstract |
The present disclosure includes, inter alia, administering an effective amount of a C5 inhibitor, such as eculizumab or an eculizumab variant, to a patient following or following vaccination with a Neisseria meningococcal type B specific vaccine. The invention relates to a method of treating a patient in need of treatment with an agent or to inhibiting the formation of terminal complement in a patient. A method of vaccinating a patient being treated with eculizumab or an eculizumab variant, the first of the eculizumab or eculizumab variant 14 ± 3 days before or after the administration of the eculizumab or eculizumab variant Also provided is a method comprising administering a Neisseria meningococcal type B specific vaccine prior to about 14 days after administration. |